Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1458-1462

  Irish, W ^a   Sherrill, B ^a   Cole, B ^b   Gard, C ^c   Glendenning, G A ^d   Mouridsen, H ^d  

^a RTI INTERNATIONAL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Letrozole; Q TWiST; Quality adjusted survival; Tamoxifen

Indexed keywords

LETROZOLE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

EID: 24044544601     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi275     Document Type: Article

References (10)

1. Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114: 621-628.
2. Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. Control Clin Trials 1993; 14: 485-499.
3. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 1993; 19: (Suppl A) 73-84.
4. Gelber RD, Goldhirsch A, for the Ludwig Breast Study Group. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772-1779.
5. Goldhirsch A, Gelber RD, Simes RJ et al. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
6. Glasziou PP, Simes RJ, Gelber RD. Quality-adjusted survival analysis. Stat Med 1990; 9: 1259-1276.
7. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. J Clin Oncol 2001; 19: 2596-2606.
8. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
9. Mounier N, Ferme C, Fletchner H et al. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making 2003; 23: 54-66.
10. Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 2004; 14: 111-124.